

TARGET PRODUCT PROFILES FOR NEEDED ANTIBACTERIAL AGENTS:

enteric fever, gonorrhoea, neonatal sepsis,
urinary tract infections and meeting report



World Health
Organization

TARGET PRODUCT PROFILES FOR NEEDED ANTIBACTERIAL AGENTS:

enteric fever, gonorrhoea, neonatal sepsis,
urinary tract infections and meeting report



World Health
Organization

Target product profiles for needed antibacterial agents: enteric fever, gonorrhoea, neonatal sepsis, urinary tract infections and meeting report

ISBN 978-92-4-000389-7 (electronic version)

ISBN 978-92-4-000390-3 (print version)

© World Health Organization 2020

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization.

Suggested citation. Target product profiles for needed antibacterial agents: enteric fever, gonorrhoea, neonatal sepsis, urinary tract infections and meeting report. Geneva: World Health Organization; 2020. Licence: [CC BY-NC-SA 3.0 IGO](https://creativecommons.org/licenses/by-nc-sa/3.0/igo).

Cataloguing-in-Publication (CIP) data. CIP data are available at <http://apps.who.int/iris>.

Sales, rights and licensing. To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <http://www.who.int/about/licensing>.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

Printed in Switzerland.

Contents

	Acknowledgements	iv
	Financial support	iv
1	EXPERT MEETING ON TARGET PRODUCT PROFILES FOR NEEDED ANTIBACTERIAL AGENTS 3-4 OCTOBER 2019, GENEVA, SWITZERLAND, MEETING REPORT	1
	Introduction	1
	The TPP development process	2
	Summary of the meeting proceedings	3
	Summary of discussions	3
	Conclusion	5
2	TARGET PRODUCT PROFILE FOR THERAPY OF UNCOMPLICATED ENTERIC FEVER	7
	Introduction	7
	Disease burden	7
	Antibiotic resistance	7
	Available treatment options	7
	Therapies in development	7
	Purpose of the TPP	8
	Access and affordability	8
	TPP for therapy of uncomplicated enteric fever	9
3	TARGET PRODUCT PROFILE FOR THERAPY OF DIAGNOSED UNCOMPLICATED GONORRHOEA	11
	Introduction	11
	Disease burden	11
	Antibiotic resistance	11
	Available treatment options	11
	Therapies in development	12
	Purpose of the TPP	12
	Access and affordability	12
	TPP for therapy of diagnosed uncomplicated gonorrhoea	13
4	TARGET PRODUCT PROFILE FOR THERAPY OF NEONATAL SEPSIS IN HIGH RESISTANCE SETTINGS	15
	Introduction	15
	Disease burden	15
	Antibiotic resistance	15
	Available treatment options	15
	Therapies in development	16
	Purpose of the TPP	16
	Access and affordability	16
	TPP for therapy in children including neonates with MDR Gram-negative infections	17
5	TARGET PRODUCT PROFILES FOR ORAL THERAPY OF URINARY TRACT INFECTIONS	19
	Introduction	19
	Disease burden	19
	Antibiotic resistance	19
	Available treatment options	19
	Therapies in development	20
	Purpose of the TPPs	20
	Access and affordability	20
	TPP for oral therapy of acute uncomplicated UTI (cystitis)	22
	TPP for oral therapy of acute pyelonephritis	23

Acknowledgements

The project was led by Ingrid Smith (WHO/ Department of Global Coordination and Partnership (GCP)/Antimicrobial Resistance (AMR)), under the supervision of Peter Beyer (WHO/GCP/AMR). Ursula Theuretzbacher (WHO consultant and Center for Anti-Infective Agents, Austria) was the leading scientific expert and prepared the scoping and draft TPP documents. GCP would like to thank experts from the following WHO Departments - Health Products, Policy and Standards; Immunization, Vaccines and Biologicals; Global HIV, Hepatitis and

STI Programmes; and Maternal, Newborn, Child & Adolescent Health and Ageing for their input and active participation throughout the process. WHO would also like to thank all the experts in the scientific advisory group as well as all external organizations and individuals who provided comments on the scoping documents and feedback on the draft TPP documents during the public consultation. In compliance with WHO transparency procedures, the feedback received during the public consultation on the TPP documents was made publicly available.

Financial support

Funding for this project was kindly provided by GARDP and by the Governments of Germany and Norway.

Expert meeting on target product profiles for needed antibacterial agents

3–4 October 2019, Geneva, Switzerland

Meeting report

Introduction

This is the report of the scientific advisory group meeting on the development of target product profiles (TPPs) for needed antibacterial agents for enteric fever (typhoid fever), gonorrhoea, neonatal sepsis and urinary tract infections, that took place in Geneva, Switzerland, on 3–4 October 2019.

Antimicrobial resistance (AMR) has increased worldwide in recent decades, limiting treatment options for many bacterial infections. In 2015, AMR was recognized as a global public health challenge with the adoption of the Global Action Plan (GAP) by the sixty-eighth World Health Assembly, providing countries with a blueprint for action to combat AMR both nationally and internationally.¹

In response to GAP objective 5, WHO developed the *Global priority list of antibiotic-resistant bacteria* and the report *Antibacterial agents in*

clinical development in 2017, and the report *Antibacterial agents in preclinical development* in 2019, to provide evidence-based guidance and a public health perspective in developing new antibacterial therapies.^{2,3}

WHO has subsequently formulated TPPs to meet the need for specific antibacterial agents. TPPs are used by drug developers to provide strategic guidance for product development programmes, and to specify the intended use, target populations and desired attributes of potential new products. In the regulatory context, TPPs help to frame development in relation to submission of product dossiers. In the context of public health, WHO TPPs set R&D targets for funders and developers by outlining the desired performance and operational characteristics of potential new products.

¹ Global action plan on antimicrobial resistance. Geneva: World Health Organization; 2015 (<https://www.who.int/antimicrobial-resistance/global-action-plan/en/>, accessed 23 January 2020).

² Prioritization of pathogens to guide discovery, research and development of new antibiotics for drug-resistant bacterial infections, including tuberculosis. Geneva: World Health Organization; 2017 (WHO/EMP/IAU/2017.12; https://www.who.int/medicines/areas/rational_use/prioritization-of-pathogens/en/, accessed 23 January 2020).

³ Antibacterial agents in clinical development: an analysis of the antibacterial clinical development pipeline, including tuberculosis. Geneva: World Health Organization; 2017 (WHO/EMP/IAU/2017.12; https://www.who.int/medicines/areas/rational_use/antibacterial_agents_clinical_development/en/, accessed 23 January 2020).

The TPP development process

The TPPs for new antibacterial agents were developed in line with the standard WHO procedure for TPPs (Fig. 1). In January 2019, an interdepartmental meeting of WHO experts was held, identifying five clinical syndromes for which new antibacterial therapies are urgently needed due to increased resistance to existing therapies. These five clinical syndromes are neonatal sepsis, gonorrhoea, typhoid fever, urinary tract infections (UTIs) and intensive care unit (ICU) patient-focused indications.

WHO then developed scoping documents for each of these five clinical syndromes, followed by an internal consultation with the WHO departments – Health Products, Policy and Standards; Immunization, Vaccines and Biologicals; Global HIV, Hepatitis and STI Programmes; and Maternal, Newborn, Child & Adolescent health and Ageing. This was followed by an external consultation process involving a broad set of clinical and drug-development experts. The proposed ICU patient-focused indication TPP was thereafter removed, as the scope was considered too broad. WHO prepared draft TPP documents for the remaining four clinical syndromes, reflecting the written comments received from the internal WHO experts.

A scientific advisory group of senior scientists, clinical and product development experts, public health officials and regulators was established following

the WHO standard procedure for TPPs regarding geographical and gender balance, diversity in expertise and management of conflict of interest (see Annex 1). This group provided written feedback on the draft TPP documents, which, together with the feedback from the internal WHO consultation, informed subsequent amendments of the draft TPPs. From 1 to 29 September 2019, WHO published the following draft TPP documents for public consultation:

- empirical therapy of neonatal sepsis in high-resistance settings/targeted therapy for multidrug-resistant (MDR) Gram-negative neonatal sepsis;
- therapy of diagnosed uncomplicated gonorrhoea;
- therapy of uncomplicated typhoid fever; and
- oral therapy of acute uncomplicated UTI.

Following the public consultation period, WHO convened a face-to-face meeting of the scientific advisory group and the relevant internal WHO experts on 3–4 October 2019 in Geneva, Switzerland, to discuss the draft TPPs, validate the feedback received from the public consultation and update the TPP documents accordingly (Fig. 2). The list of participants is detailed in Annex 1.

Fig. 1. TPP development process

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_24604

